Other Mutations: PD-L1

NCT05382286: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: PD-L1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients who have previously received topoisomerase 1 inhibitors, including antibody drug conjugates (e.g. Irinotecan hydrochloride, Etirinotecan pegol, datopotamab deruxtecan/Dato-DXd/DS-1062a, Enhertu/Trastuzumab deruxtecan)
https://ClinicalTrials.gov/show/NCT05382286

NCT05233696: Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

NCT05233696
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: PD-L1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have at least one site of disease amenable to radiation therapy
Exclusions: Patients with more than one prior line of chemotherapy in the locally advanced unresectable or metastatic setting; Patients with prior treatment with a taxane in the metastatic setting; Patients with symptomatic, unstable, untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT05233696

Up ↑